Search
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalTazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a vari...
Mixtures: AUROTAZ-P 4.5 G, Aurotaz-P Powder for Injections 4.5 gZuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalZuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEtoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnEtoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inh...
Synonyms: 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalRoflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesGepirone
go.drugbank.com/drugs/DB12184ApprovedGepirone, an azapirone, is a pharmacologic analog of buspirone that acts selectively on the pre- and post-synaptic 5HT1A receptors. Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-r...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalHormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalBexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is ...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates